Trump Signs Order Fast-Tracking Review of Psychedelic Treatments for Mental Health

US President Donald Trump has signed an executive order aimed at accelerating the review of psychedelic substances for potential use in treating mental health disorders.

The order, which was announced on [date], instructs federal agencies to expedite research into the therapeutic applications of psychedelics such as LSD, psilocybin, and ibogaine. The goal is to increase access to these substances for individuals suffering from conditions like depression, anxiety, and post-traumatic stress disorder.

The executive order also calls on the Food and Drug Administration (FDA) to explore the possibility of approving psychedelic-based treatments for certain mental health disorders. This could potentially pave the way for more widespread use of psychedelics in medical settings.

The move has been met with interest from researchers and advocates who believe that psychedelics may hold promise as a new class of treatments for mental health conditions. However, it is unclear at this time what specific actions will be taken under the executive order or how quickly they will be implemented.

The White House has not provided further details on the scope and timeline of the research initiatives outlined in the executive order.

Source: Google News World